Researchers analyzed data from 1,540 patients with Parkinson's disease to see how the medication tavapadon affected movement. The study included both people in the early stages of the disease and those already taking levodopa who experienced motor fluctuations.
For those in the early stages, results showed a measurable improvement in motor function scores compared to a placebo. For patients already on levodopa, the use of tavapadon was linked to an increase in 'ON-time,' which is the period when symptoms are well-managed. However, the evidence for some side effects and specific conditions like sleepiness remains uncertain.
Some safety concerns were noted during the study. Patients taking tavapadon reported higher rates of nausea and dizziness compared to those on a placebo. Additionally, more people stopped taking the medication during the trial period. Because these results come from a meta-analysis with limited follow-up times, you should talk to your doctor about how this specific medication might fit into an individual treatment plan.
